

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
4 January 2001 (04.01.2001)

PCT

(10) International Publication Number  
**WO 01/00819 A1**

- (51) International Patent Classification<sup>7</sup>: C12N 15/10, [IN/US]; 384 Egypt Run Road, Landenberg, PA 19350 (US), 15/90, 15/67
- (21) International Application Number: PCT/US00/17154 (74) Agent: FLOYD, Linda, Axaemy; E.I. Du Pont de Nemours and Company, Legal Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).
- (22) International Filing Date: 21 June 2000 (21.06.2000)
- (25) Filing Language: English (81) Designated States (national): CA, US.
- (26) Publication Language: English (84) Designated States (regional): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
- (30) Priority Data: 60/141,103 25 June 1999 (25.06.1999) US
- (71) Applicants (for all designated States except US): E.I. DU PONT DE NEMOURS AND COMPANY [US/US]; 1007 Market Street, Wilmington, DE 19898 (US). GENENCOR INTERNATIONAL, INC. [US/US]; 200 Meridian Centre Boulevard, Rochester, NY 14618 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): CHAUHAN, Sarita

**Published:**

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



**WO 01/00819 A1**

(54) Title: TARGETED GENE REPLACEMENTS IN ENTERIC BACTERIA USING LINEAR DNA

(57) Abstract: The present invention provides a rapid and specific method for targeted gene replacement in bacteria. The modified or disrupted genes or other nucleic acid fragments are transformed into their desired hosts and the transformants are screened for desired integrations using a selectable marker for an altered phenotype. More specifically, the instant invention creates site-directed mutants of enteric bacteria by allelic exchange to identify an altered phenotype that will define the function or effect of the mutated gene. This invention also describes how linear DNA fragments harboring a functional gene can be used for replacement of a mutant gene to restore gene functionality.

TITLE  
TARGETED GENE REPLACEMENTS IN  
ENTERIC BACTERIA USING LINEAR DNA  
FIELD OF THE INVENTION

5           The present invention relates to the field of molecular biology and microbiology. More specifically, methods have been developed for the introduction of site-directed alterations in the *Escherichia coli* genome using linear DNA molecules to generate stable transformants.

BACKGROUND OF THE INVENTION

10           With the advent of large scale genome sequencing efforts, enormous amounts of sequence information are being made available to the research community. Genome sequencing efforts have been completed for several prokaryotes including *Escherichia coli*. At least 46 genomes of different genera of bacteria of industrial, pharmaceutical and agricultural importance, have been  
15 completely sequenced and about 70 are in progress  
(<http://www.ncbi.nlm.nih.gov/PMGifs/Genomes/bact.html>). However, only a small portion of the genes sequenced from all these efforts have been functionally characterized.

          The need for discovery and analyses of gene function has spawned several  
20 new areas of research referred to as functional genomics, proteomics, and metabolomics. Functional genomics seeks to discover gene function once nucleotide sequence information is available. Proteomics (the study of protein properties such as expression, post-translational modifications, interactions, etc.) and metabolomics (analysis of metabolite pools) are fast-emerging fields  
25 complementing functional genomics, that provide a global, integrated view of cellular processes. The variety of techniques and methods used in this effort include the use of bioinformatics, gene-array chips, mRNA differential display, disease models, protein discovery and expression, and target validation. The ultimate goal of many of these efforts has been to develop high-throughput  
30 screens for genes of unknown function.

          A variety of techniques have been applied to elucidate gene function including identifying the interacting protein partner of a gene product as in the yeast 2-hybrid system (Bolger, G., *Methods Mol. Biol.* 88:101-131 (1998)) and transposon tagging which is useful in both microbial and eukaryotic genomes  
35 (Kumar et al., *Plant Biotechnol.* 15:159-165 (1998)). The logarithmic increase in sequence data has driven the need for high-throughput (HTP) functional genomics screens. However, relatively few HTP methods have been developed to date.

Traditional methods for the determination of gene function still remain the basis of the functional genomics effort.

Classically, the first and most basic analysis for any gene is to assess the phenotype of the organism when the gene of interest is altered or rendered  
5 nonfunctional. The impact of such alterations as well as knockouts on proteome or metabolome can be measured to understand gene function. The "null mutations" are often constructed by gene disruption (also called gene knockouts) by homologous recombination resulting in allelic exchange or gene replacement. Gene disruption vectors are constructed by recombinant DNA techniques. Upon  
10 transformation into the organism the DNA construct with disrupted gene integrates at the resident location in the genome by homologous recombination and replaces the functional copy of the gene with the nonfunctional disrupted gene. Gene disruption vectors are constructed from a genomic clone containing the gene of interest, using a vector that does not replicate in the host organism to  
15 be mutated. The final disruption construct has 1) a selectable marker inserted in and/or around the gene of interest in a manner that eliminates expression of the gene of interest or renders non-functional any protein product that is produced, and 2) additional unmodified genomic DNA flanking the gene disruption site of interest that helps target integration events to the disruption site. Gene disruption  
20 vectors have been constructed for microbial and mammalian systems by (i) identifying and isolating a genomic clone containing the gene of interest; (ii) determining convenient restriction sites within or flanking the gene; (iii) subcloning a selectable marker into the gene at the restriction sites thereby inactivating the gene; (iv) transforming the altered gene containing the marker into  
25 the host organism; and (v) screening the transformant for an altered phenotype (see for example Sedivy et al., *Proc. Natl. Acad. Sci. USA* 86:227-31 (1989)).

The above process has worked well for disruption of genes in a range of organisms but has several inherent limitations. First, a genomic clone of suitable length must be isolated from a suitable library, most often by hybridization or  
30 cloned by PCR into a suitable plasmid. Second, the methodology is completely limited to existing restriction sites which must be compatible with the selectable marker to be ligated and must occur in positions such that ligation of the selectable marker makes the gene of interest nonfunctional. Additional restriction sites that occur outside the gene of interest can make cloning of the selectable  
35 marker into the genomic DNA very difficult. Third, because this process relies on traditional restriction analysis and cloning, it is inherently a labor intensive, one-gene-at-a-time approach. Fourth, cosuppression or quelling (Cogoni et al., *EMBO J.* 15:3153-3163 (1996)), a gene silencing phenomenon seen in fungi and plants

can result when a gene disruption vector leaves the promoter and part of the 5' coding region intact. Fifth, these methods often give unpredictable results. For example, a desired gene targeting will result in replacement of the functional allele with a null mutation results. If, however, non-targeted, ectopic integration occurs (and this undesired integration often predominates) then the transformant harbors both a functional and nonfunctional copy of the gene. Yeast and *Escherichia coli* have previously been used for *in vivo* cloning for double strand break repair or gap repair (Oldenber et al., *Nucleic Acids Research* 25:451-452 (1997); Hua et al., *Plasmid* 38:91-96 (1997); Oliner et al., *Nucleic Acids Research* 21:5192-5197 (1993); Bubeck et al., *Nucleic Acids Research* 21:3601-3602 (1993)). In these repair mechanisms, a restriction enzyme-linearized plasmid is cotransformed with a piece of DNA with homology to either side of the gap. This method of construction requires, and is limited by, knowledge of restriction enzyme sites in the genomic DNA. Yeast and *Escherichia coli* can efficiently use this homology to repair the gap and produce a functional circular plasmid. Although these methods are effective, they are time consuming, often requiring several months of work, and require a detailed endonuclease restriction map prior to the analysis. Further, these approaches are not easily adapted to the high-throughput methodology needed today.

An alternative to the restriction analysis and subcloning methods are available where the host organism is capable of efficient homologous recombination (e.g., yeast). While most organisms require a minimum of several kilobase of homologous sequence to target integration, *Saccharomyces cerevisiae* requires more limited amounts of homology to target integration to the chromosome. Thus, a selectable marker can be amplified by PCR with targeting homology (60 bp on each side) incorporated in the PCR primers, thus avoiding the need for restriction analysis and subcloning with a large isolated genomic clone (Manivasakam et al., *Nucleic Acids Research* 23:2799-2800 (1995)). This method is the basis of an effort by the yeast researchers worldwide to disrupt all 6000+ genes in this organism. This method is practiced with normal yeast chromosomes as well as with artificial chromosomes. Treco et al. (U.S. 5,783,385) teach the identification and isolation of target DNA fragments from yeast artificial chromosome (YAC) yeast libraries, relying on the homologous recombination of transformed non-replicating plasmid DNA with the yeast genome.

Yeast provides a particularly efficient environment for homologous recombination events between genetic elements especially using linear DNA, although similar methods have been developed in bacterial organisms. For example, Zhang et al., (*Nat. Genet.* 20:123-128 (1998)) teach the site-specific

manipulation of target DNA by homologous recombination between linearized and chromosomal DNA (as well as plasmids and large episomes) in *Escherichia coli sbcA* mutants expressing RecE and RecT. These methods are useful, but require use of special mutant strains of *E. coli* that reduce the level of DNA damaging endonucleases which may digest foreign, linearized constructs.

5 Murphy, K. C., (*J Bacteriol.* 180:2063-2071(1998)) have reported the use of  $\lambda$  recombination system (Red) for generating gene knockouts in *Escherichia coli* using linearized DNA. However, use of this system for mutagenesis suffers from requirement of extra steps for transfer of  $\lambda$  Red functions to the host strain that needs to be mutated.

Several reports including the above mentioned have demonstrated that in the absence of specialized genetic backgrounds, integration of disrupted genes by allelic exchange does not occur in *Escherichia coli* genome.

15 El Karoui et al. (*Nucleic Acids Res.* 27:1296-1299 (1999), and 8<sup>th</sup> Int'l. Symp. on the Genetics of Industrial Microorganisms, 28 June 1998) report that gene replacements using linear double-stranded DNA can be achieved in wild-type *Escherichia coli* if electrocompetent cells are used.

The problem to be solved is to provide a convenient method without the limitations of known techniques to create site-directed mutants of *Escherichia coli* (or other bacteria) by allelic exchange using linear fragments of DNA to identify an altered phenotype that will define the function or effect of the mutated gene. Traditionally, the production of *Escherichia coli* mutants has been accomplished utilizing suicide vectors, which requires cloning of the gene disrupted with a selectable marker in such a vector. Winans et al. (*J. Bacteriol.* 161:1219-1221 (1985)) have shown that site-directed mutants of *Escherichia coli* strains can be obtained using linearized fragments of DNA containing a selectable marker flanked by homologous DNA. However, these examples assert the requirement of specific genetic backgrounds (e.g., *recB*, *recC* and/or *sbcB*). The *recB* and *recC* mutations inactivate exonuclease, preventing it from degrading the linear DNA, whereas the *sbcB* mutation restores recombination proficiency in a strain which carries *recB* and *recC* mutations.

Although the above traditional methods permit generation of reliable site-directed mutants, there are clear disadvantages to both methods. The first one requires cloning into suicide vectors, which are available for only very limited number of bacteria. Additionally it requires an extra cloning step and is time consuming. Another disadvantage of suicide vectors in gene replacement efforts is that considerable background results due to single recombination events. The second method of Winans et al. suffers from having to use special genetic

backgrounds which, for several reasons may not be desirable when the organism to be mutated is *E. coli*, or not available at all (i.e., most bacteria other than *Escherichia coli*).

#### SUMMARY OF THE INVENTION

5 This invention provides a method for targeted DNA replacement in bacteria comprising introducing into a recombination-proficient bacteria a replacement cassette of DNA comprising a 5' recombinant region and a 3' recombinant region, each region independently at least 75% identical to a DNA target region of the bacteria. The replacement cassette may or may not  
10 additionally include a functional gene positioned between the two recombinant regions that upon integration into host restores gene functionality. The basis for screening is the phenotypic effect of a selectable marker that results from integration of the replacement cassette in the target sequence. Useful application of this method is to carry out site-directed DNA replacements for generation of  
15 desired DNA modifications in bacteria.

#### BRIEF DESCRIPTION OF THE DRAWINGS AND SEQUENCE DESCRIPTIONS

The invention can be more fully understood from the following detailed description and the accompanying Figures and Sequence Listing which form a  
20 part of this application.

Figure 1 shows a schematic diagram of *E. coli* genomic DNA region that harbors *yciK* gene, the location of *yciK* ORF with respect to restriction sites relevant to gene constructions in this invention. Location of primers used for  
25 amplifying *yciK* DNA for pyciKCK, pSCyciK1 and for knockout confirmations, is shown along with their Seq IDs.

Figure 2 shows the plasmid construct pSCyciK1. *yciK* DNA flanked with engineered *HindIII* and *XhoI* sites was cloned into vector pBluescript II SK (+).

Figure 3 shows a schematic diagram of *HinCII* fragment of pLoxCat1 with relevant restriction sites used in engineering pyciKcat2 and pyciKcat3 and for  
30 confirmations of chloramphenicol resistance marker (SEQ ID NO:7) in mutants. Location and direction of *cat* ORF is shown as an arrow.

Figure 4 shows the plasmid construct pyciKcat2. The *HinCII* fragment from *yciK* region (See Figure 1) was replaced with the 1.2 kb *HinCII-SmaI* fragment of pLoxCat1. *cat* gene is in opposite orientation to *yciK* gene.

35 Figure 5 shows the plasmid construct pyciKcat3 engineered same as above. However, here *cat* gene is in same direction as *yciK* gene.

Figure 6 is a gel confirming *yciK* knockouts by genome-specific PCR.

Figure 7 is a gel confirming *yciK* knockouts by Southern hybridization of *Sst*II digested genomic DNA from wild-type and mutant *E. coli* probed with SEQ ID NO:18.

5 Figure 8 shows a schematic diagram to describe Overlap-Extension PCR to generate *tpiA* deletion.

Figure 9 shows the plasmid construct pRN106-2. A 2004 bp overlap extension PCR product with 73% of the *tpiA* structural gene deleted (Figure 8) was cloned into pCR-Blunt (Invitrogen) to yield the 5517 bp plasmid pRN106-2. The two extreme ends of *tpiA* are shown with an engineered *Sca*I site in between.

10 Figure 10 shows the plasmid construct pRN107-1, the source of the linearized DNA fragment used to generate the *tpiA* knockout. The 1.2 kb *Hin*CII fragment from pLoxCat1 containing the loxP-CmR-loxR cassette was inserted into the *Sca*I site of pRN106-2 to yield the 6763 bp plasmid pRN107-1. Using pRN107-1 as template and primers SEQ ID NO:1 and SEQ ID NO:4, the 3246 bp  
15 fragment containing *tpiA* flanking regions and the loxP-CmR-loxP cassette was PCR-amplified and this linear DNA fragment was used to transform KLP23 to generate *tpiA* mutants by double crossover.

Figure 11 shows the design for confirmation of *tpiA* knockouts by genome-specific PCR.

20 Applicant(s) have provided 19 sequences in conformity with 37 C.F.R. 1.821-1.825 ("Requirements for Patent Applications Containing Nucleotide Sequences and/or Amino Acid Sequence Disclosures – the Sequence Rules") and consistent with World Intellectual Property Organization (WIPO) Standard ST2.5 (1998) and the sequence listing requirements of the EPO and PCT  
25 (Rules 5.2 and 49.5(a-bis), and Section 208 and Annex C of the Administration Instructions).

SEQ ID NO:1 is the nucleotide sequence of DNA fragment containing *yciK* gene.

30 SEQ ID NO:2 is the forward primer for amplification of the *yciK* gene from the *Escherichia coli* genome.

SEQ ID NO:3 is the reverse primer for amplification of the *yciK* gene from the *Escherichia coli* genome.

SEQ ID NO:4 forward primer with *Hind*III site.

SEQ ID NO:5 reverse primer with *Xho*I site.

35 SEQ ID NO:6 is the nucleotide sequence of the *yciK* fragment flanked with *Hind*III and *Xho*I sites.

SEQ ID NO:7 is the *Hin*CII fragment of pLoxCat1.

SEQ ID NO:8 is the deduced amino acid sequence encoded by *yciK* open reading frame.

SEQ ID NO:9 is the forward primer used in a PCR reaction to confirm *yciK* knockout.

5 SEQ ID NO:10 is the reverse primer used in a PCR reaction to confirm *yciK* knockout.

SEQ ID NO:11 is a primer between *sbp* and *cdh*.

SEQ ID NO:12 is a primer within *tpiA* 3' region.

10 SEQ ID NO:13 is a primer within *tpiA* 5' region with an introduced *ScaI* site.

SEQ ID NO:14 is a primer within *yiiR* 5' region.

SEQ ID NO:15 is a primer at 5' end of *sbp*.

SEQ ID NO:16 is a primer at 3' end of *yiiR*.

15 SEQ ID NO:17 is expected PCR fragment when SEQ ID NO:9 and SEQ ID NO:10 were used as primers with *Escherichia coli* genomic DNA as template.

SEQ ID NO:18 is a 969bp *SstII* fragment of *yciKCK*.

SEQ ID NO:19 is the sequence of expected band in Southern experiment when *SstII* digested wild-type genomic DNA is probed with 969bp *SstII* fragment (SEQ ID NO:18) of *yciKCK*.

20 DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a rapid and specific method for the modification or disruption of genes or other nucleic acid fragments. The thus-modified or disrupted genes may then be transformed into their native hosts and screened for an altered phenotype, indicating gene function. The invention creates  
25 stable site-directed alterations in *E. coli* or other gram negative enteric bacterial genome by allelic exchange using linear fragments of DNA to identify an altered phenotype that will define the function or effect of the mutated gene. The invention does not have the limitations of the prior art with regard to time and restriction to specific genetic backgrounds.

30 Additionally the present method has application in the areas of functional genomics, proteomics, metabolomics where gene disruptions to reveal function of unknown genes (and their products) or unknown function of known genes (and their products) or other functional DNA elements is desirable. Similarly the present method may be used for metabolic engineering in techniques such as gene  
35 silencing by disruption, gene integration or replacement to add genes of new function or to replace a defective gene with a functional gene. In similar fashion the present method may be useful to regulate or modify genes or operons by



altering or modifying regulatory sequences such as promoters, ribosomal binding sites, terminators, and enhancers, for example.

In this disclosure, a number of terms and abbreviations are used. The following definitions are provided.

5       “Polymerase chain reaction” is abbreviated PCR.

      “Open reading frame” is abbreviated ORF.

      “Isopropyl  $\beta$ -D-Thiogalactoside” is abbreviated IPTG.

      “Sodium dodecyl sulfate” is abbreviated SDS.

      “Luria-Bertani” is abbreviated LB.

10       “Gene” refers to a nucleic acid fragment that expresses a specific RNA only or a specific RNA and protein, including regulatory sequences preceding (5' noncoding sequences) and following (3' noncoding sequences) the coding sequence. The terms “synthetic genes” and “synthetic DNA” refer to genes and DNA that can be assembled from oligonucleotide building blocks that are  
15       chemically synthesized using procedures known to those skilled in the art. These building blocks are ligated and annealed to form gene constructs. “Chemically synthesized”, as related to a sequence of DNA, means that the component nucleotides were assembled in vitro. Manual chemical synthesis of DNA may be accomplished using well established procedures, or automated chemical synthesis  
20       can be performed using one of a number of commercially available machines. “Gene constructs” may contain a full gene or less or more than a full gene.

      The term “gene disruption” is used interchangeably with the term “gene knock out” to refer to the process of interfering within a gene such that no functional gene product is expressed.

25       The term “gene replacement” refers to a process which replaces a gene with either a functional or a mutated gene such that either no gene product is expressed or a mutant gene product is expressed.

      The term “DNA replacement” means a process in which one fragment of DNA is replaced with another DNA fragment.

30       The term “gene modification” means any process where a gene is altered in any way including gene disruption or gene replacement.

      The term “gene targeting” refers to a process where a specific site within a gene or nucleic acid fragment is identified or targeted on the basis of sequence.

35       The term “nucleic acid fragment” refers to a polymer of RNA or DNA that is single- or double-stranded, optionally containing synthetic, non-natural or altered nucleotide bases. A nucleic acid fragment in the form of a polymer of DNA may be comprised of one or more segments of cDNA, genomic DNA, or synthetic DNA. A nucleic acid fragment may be a portion of a gene, may be

synthetic, or may be a genetic regulatory element. A “target nucleic acid fragment” or “target gene” or “target DNA” is any nucleic acid fragment that is inserted into a modification plasmid that is targeted for modification or disruption.

The terms “plasmid”, “vector”, and “cassette” refer to an extra  
5 chromosomal element often carrying genes which are not part of the central metabolism of the cell, and usually in the form of circular double-stranded DNA molecules. Such elements may be autonomously replicating sequences, genome integrating sequences, phage or nucleotide sequences, linear or circular, of a single- or double-stranded DNA or RNA, derived from any source, in which  
10 a number of nucleotide sequences have been joined or recombined into a unique construction which is capable of introducing a promoter fragment and DNA sequence for a selected gene product along with appropriate 3' untranslated sequence into a cell. “Transformation cassette” refers to a specific vector containing a foreign gene and having elements in addition to the foreign gene that  
15 facilitate transformation of a particular host cell. “Expression cassette” refers to a specific vector containing a foreign gene and having elements in addition to the foreign gene that allow for expression of that gene in a foreign host.

The term “selectable marker” refers to those genes encoding proteins that may be expressed and/or which convey a phenotype on the host that enables  
20 selection. A defective or functional gene may itself act as a selectable marker if its presence leads to a phenotype that can be selected against the background. “Background” is undesirable colonies that appear during screening of gene replacement events. The term “modification plasmid” refers to a specialized plasmid for use in the present invention comprising, at a minimum, a plasmid-  
25 specific marker and a replacement cassette.

“Enteric-specific selectable markers” are those genes encoding proteins that may be expressed in Enteric bacteria (e.g., *Salmonella* sp., *Escherichia* sp.), which convey a phenotype on the enteric host that enables selection. “Enteric bacteria” are members of the family *Enterobacteriaceae*, and include such  
30 members as *Escherichia*, *Salmonella*, and *Shigella*. They are gram-negative straight rods, 0.3-1.0 X 1.0-6.0  $\mu\text{m}$ , motile by peritrichous flagella, except for *Tatumella*, or nonmotile. They grow in the presence and absence of oxygen and grow well on peptone, meat extract, and (usually) MacConkey’s media. Some grow on D-glucose as the sole source of carbon, whereas others require vitamins  
35 and/or mineral(s). They are chemoorgano-trophic with respiratory and fermentative metabolism but are not halophilic. Acid and often visible gas is produced during fermentation of D-glucose, other carbohydrates, and polyhydroxyl alcohols. They are oxidase negative and, with the exception of

*Shigella dysenteriae* 0 group 1 and *Xenorhabdus nematophilus*, catalase positive. Nitrate is reduced to nitrite except by some strains of *Erwinia* and *Yersina*. The G + C content of DNA is 38-60 mol % ( $T_m$ , Bd). DNAs from species from species within most genera are at least 20% related to one another and to

5 *Escherichia coli*, the type species of the family. Notable exceptions are species of *Yersina*, *Proteus*, *Providencia*, *Hafnia* and *Edwardsiella*, whose DNAs are 10-20% related to those of species from other genera. Except for *Erwinia chrysanthemi* all species tested contain the enterobacterial common antigen (Bergy's Manual of Systematic Bacteriology, D. H. Bergy, et al., Baltimore:

10 Williams and Wilkins, 1984).

The terms "KO vector" or "knock out vector" refer to a modification plasmid lacking the target gene to be modified.

The term "knock out plasmid" refers to a modification plasmid that contains a gene targeted for disruption.

15 The term "knock out cassette" refers to a modification cassette that contains recombination regions designed to insert a modifying nucleic acid within the coding region of the target gene so as to prevent the effective expression of that target gene.

A "replacement cassette" refers to a specialized DNA cassette that

20 comprises at a minimum, a selectable marker, a modifying DNA and 5' and 3' recombination regions. Replacement cassettes may optionally also comprise other modifying DNA or RNA sequences, inserted between the flanking recombination regions. Within the context of the present invention, replacement cassettes containing modifying DNA interact with the DNA to be replaced via the

25 mechanism of homologous recombination to permit modification or disruption of the target gene or target nucleic acid.

The term "genomic host" refers to the cell or host from which the target gene or DNA has been cloned.

The term "inserting nucleic acid fragment" refers to a DNA ("inserting

30 DNA fragment") or RNA ("inserting RNA fragment") molecule residing in a replacement cassette that is useful for the modification or disruption of a target gene or target nucleic acid fragment. The inserting nucleic acid fragment will insert at a site directed by the sequence of the recombination regions on the cassette. "Inserting DNA" may be either "modifying" or "disrupting".

35 "Modifying DNA" or "modifying nucleic acid fragments" will result in the altering of the composition or function of a target gene but will not disrupt the gene. "Disrupting DNA" or "disrupting nucleic acid fragments" will have the effect of disrupting the target gene of interest. "Modifying DNA" or "disrupting

DNA” will include but will not be limited to non-specific DNA or RNA sequences, selectable markers, origins of replication, antisense sequences and regulatory elements. As used herein, “regulatory elements” refer to nucleotide sequences located upstream (5'), within, and/or downstream (3') to a coding sequence, which control the transcription and/or expression of the coding sequences, potentially in conjunction with the protein biosynthetic apparatus of the cell. In artificial DNA constructs regulatory elements can also control the transcription and stability of antisense RNA. One specific regulatory element is a “promoter”. “Promoter” refers to a DNA sequence capable of controlling the expression of a coding sequence or functional RNA. In general, a coding sequence is located 3' to a promoter sequence. Promoters may be derived in their entirety from a native gene, or be composed of different elements derived from different promoters found in nature, or even comprise synthetic DNA segments. It is understood by those skilled in the art that different promoters may direct the expression of a gene in different tissues or cell types, or at different stages of development, or in response to different environmental conditions. Promoters which cause a gene to be expressed in most cell types at most times are commonly referred to as “constitutive promoters”. It is further recognized that since in most cases the exact boundaries of regulatory sequences have not been completely defined, DNA fragments of different lengths may have identical promoter activity.

The term “recombination region” refers to 3' and 5' flanking nucleic acid regions on the replacement cassette. Recombination regions are designed to be either complementary to, or have significant base identity with, the corresponding regions of the target genes or target nucleic acid fragments to be disrupted or modified. Significant identity, for example, may range from about 70% between the bases of the target gene (“target region”) and the recombination regions. Recombination regions at the 5' end of the cassette are referred to as “5' recombination regions” and recombination regions at the 3' end of the cassette are referred to as “3' recombination regions”. The maximum length of the flanking recombination region is set at approximately 150 bases when using PCR amplification in the technique.

The term “complementary” is used to describe the relationship between nucleotide bases that are hybridizable to one another. For example, with respect to DNA, adenosine is complementary to thymine and cytosine is complementary to guanine.

The term “percent identity” is a relationship between two or more polynucleotide sequences as determined by comparing the sequences. In the art, “identity” also means the degree of sequence relatedness between polynucleotide

sequences as determined by the match between strings of such sequences.

“Identity” and “similarity” can be readily calculated by known methods, including but not limited to those described in: Computational Molecular Biology (Lesk, A. M., ed.) Oxford University Press, New York (1988); Biocomputing: Informatics and Genome Projects (Smith, D. W., ed.) Academic Press, New York (1993); Computer Analysis of Sequence Data, Part I (Griffin, A. M., and Griffin, H. G., eds.) Humana Press, New Jersey (1994); Sequence Analysis in Molecular Biology (von Heinje, G., ed.) Academic Press (1987); and Sequence Analysis Primer (Gribskov, M. and Devereux, J., eds.) Stockton Press, New York (1991).

10 Preferred methods to determine identity are designed to give the largest match between the sequences tested. Methods to determine identity and similarity are codified in publicly available computer programs. Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, the GCG Pileup program found in the GCG program package, 15 as used in the instant invention, using the Needleman and Wunsch algorithm with their standard default values of gap creation penalty=12 and gap extension penalty=4 (Devereux et al., *Nucleic Acids Res.* 12:387-395 (1984)), BLASTP, BLASTN, and FASTA (Pearson et al., *Proc. Natl. Acad. Sci. U.S.A.* 85:2444-2448 (1988)). The BLAST X program is publicly available from NCBI 20 and other sources (BLAST Manual, Altschul et al., *Natl. Cent. Biotechnol. Inf., Natl. Library Med. (NCBI NLM) NIH, Bethesda, MD 20894*; Altschul et al., *J. Mol. Biol.* 215:403-410 (1990)). Another preferred method to determine percent identity, is by the method of DNASTAR protein alignment protocol using the Jotun-Hein algorithm (Hein et al., *Methods Enzymol.* 183:626-645 (1990)). 25 Default parameters for the Jotun-Hein method for alignments are: for multiple alignments, gap penalty=11, gap length penalty=3; for pairwise alignments ktuple=6. By way of illustration, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with 30 another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. These mutations of the reference sequence may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among nucleotides in the reference sequence or in 35 one or more contiguous groups within the reference sequence.

The term “a partial sequence” or “a portion of a sequence” refers to a sequence of sufficient length to permit homologous recombination according to

the conditions of the present method. Typically, “a partial sequence” or “a portion of a sequence” will range from about 15 bp to about 200 bp.

The term “coding sequence” refers to a DNA sequence that codes for a specific amino acid sequence. “Suitable regulatory sequences” refer to nucleotide  
5 sequences located upstream (5' noncoding sequences), within, or downstream (3' noncoding sequences) of a coding sequence, and which influence the transcription, RNA processing or stability, or translation of the associated coding sequence. Regulatory sequences may include promoters, translation leader sequences, introns, and polyadenylation recognition sequences.

10 The term “operably linked” refers to the association of nucleic acid sequences on a single nucleic acid fragment so that the function of one is affected by the other. For example, a promoter is operably linked with a coding sequence when it is capable of affecting the expression of that coding sequence (i.e., that the coding sequence is under the transcriptional control of the promoter). Coding  
15 sequences can be operably linked to regulatory sequences in sense or antisense orientation.

The term “operon” refers to a group of operably linked genes and regulatory elements that functions as a unit of transcription. An operon starts with a promoter, which binds RNA polymerase and initiates transcription of the  
20 operon.

The term “expression” refers to the transcription and stable accumulation of sense (mRNA) or antisense RNA derived from the nucleic acid fragment of the invention. Expression may also refer to translation of mRNA into a polypeptide.

25 The term “recombination proficient” means that a microorganism is capable of integrating extra-chromosomal DNA into its genome via homologous recombination. Additionally, a “recombination proficient” microorganism is also capable of recombining DNA resident on chromosome if sufficient homology exists between another DNA locus.

30 “Transformation” refers to the transfer of a nucleic acid fragment into the host organism. “Stable transformation” refers to integrating the nucleic acid into the genome of the cell.

35 “Absolute recombination frequencies” range from  $2.3 \times 10^{-6}$  to  $1.5 \times 10^{-1}$  in *E. coli* depending on the system and length of homology involved. *RecA* is the most crucial component for the homologous recombination reaction, although *recA* independent mechanisms also exists. Homologs and analogs of *recA*-like proteins and other genes linked to homologous recombination have been discovered in a wide range of bacteria and eukaryotes. (Lloyd, R. G. and Low,

K. B. (1996) Homologous Recombination. In *Escherichia coli* and *Salmonella* Cellular and Molecular Biology, Ed. F.C. Neidhardt, ASM Press, p 2236-2255).

For a gene replacement to occur which requires two homologous recombination event absolute recombination frequencies can be calculated to be in  
5 the range of  $10^{-12}$  to  $10^{-2}$ .

Linear DNA is the replacement cassette that is isolated from a modification plasmid by restriction digestion or by PCR amplification as described in Examples 1 and 4. Preparation of linear DNA is also described in Example 3.

10 Although linear DNA has been used for gene replacements in some bacteria such as *Bacillus subtilis*, literature has strongly indicated that gene replacements using linear DNA do not occur in wild type bacteria such as *E. coli* and *Salmonella* unless some mutations or special genes are introduced to render these organisms hyper-recombinant. Use of electroporation, offering the highest  
15 efficiencies of transformation among the presently known methods, demonstrates that linear DNA can be used for gene replacements in wild type *E. coli*. By achieving high efficiencies of transformation, gene replacements can be performed in any recombination proficient bacteria which carry a functional recombination system.

20 The present method is useful for the rapid disruption or modification of genes or other genetic elements. Genes of unknown function which are disrupted in this fashion are transformed into genomic hosts where screening for an altered phenotype will reveal their function.

This method is also useful for replacing defective or mutated genes from  
25 bacterial genome with the functional gene provided a selection phenotype exist for the function of the gene.

The gene replacement techniques described in examples to follow can also be used for regulation of genes present in operons by replacement of operably linked promoter region with a promoter of desired strength.

30 The method described in this invention to obtain gene replacement can be used in enteric bacteria without specialized host backgrounds or use of suicide vectors. Electrotransformation also constitutes a clear-cut method to obtain gene replacements with linear DNA in wild-type *Escherichia coli* on plasmid and chromosomal targets. However, any methods (chemical transformation or  
35 electrotransformation) that ensure a transformation efficiency high enough to enable the occurrence of double homologous recombination between the target DNA and the replacement cassette will work, in this specific case electrotransformation was used. The method of electrotransformation itself does not

guarantee a success in gene replacements if quality of competent cells is not good or if host strains deficient in recombination functions are used. A high efficiency of transformation must occur in recombination proficient bacteria. Depending on the absolute recombination frequencies of target gene (or target DNA) locus and  
5 the host strain, required transformation efficiencies will vary. Use of long PCR primers as described in Example 3 completely eliminates any cloning requirements for gene replacements.

Therefore, the present method is useful for the rapid disruption or modification of genes or other genetic elements. Genes of unknown function  
10 disrupted in this fashion may be transformed into genomic hosts where screening for an altered phenotype will reveal their function.

The present invention is further defined in the following Examples. It should be understood that these Examples, while indicating preferred embodiments of the invention, are given by way of illustration only. From the  
15 above discussion and these Examples, one skilled in the art can ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.

### EXAMPLES

#### 20 GENERAL METHODS

Procedures required for PCR amplification, DNA modifications by endo- and exonucleases for generating desired ends for cloning of DNA, ligations, and bacterial transformation are well known in the art. Standard recombinant DNA and molecular cloning techniques used here are well known in the art and are  
25 described by Sambrook, J., Fritsch, E. F. and Maniatis, T. Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor (1989) (hereinafter "Sambrook"); and by T. J. Silhavy, M. L. Bannan, and L. W. Enquist, Experiments with Gene Fusions, Cold Spring Harbor Laboratory Press, Cold Spring, N.Y. (1984) and by Ausubel, F. M. et al., Current Protocols in  
30 Molecular Biology, John Wiley & Sons, Inc. (1994-98).

For computational nucleic acid and protein sequence analysis Wisconsin Package Version 9.0 and 10.0, Genetics Computer Group (GCG) and Vector NTI Deluxe v4.0.3 software and database packages were used. Unless specified otherwise, all default parameters were used.

35 Materials and methods suitable for the maintenance and growth of bacterial cultures are well known in the art. Techniques suitable for use in the following examples may be found as set out in Manual of Methods for General Bacteriology (Phillipp Gerhardt, R. G. E. Murray, Ralph N. Costilow, Eugene W.



Nester, Willis A. Wood, Noel R. Krieg and G. Briggs Phillips, eds.), American Society for Microbiology, Washington, DC. (1994)) or by Thomas D. Brock, in Biotechnology: A Textbook of Industrial Microbiology, Second Edition, Sinauer Associates, Inc., Sunderland, MA (1989). All reagents, restriction enzymes and materials used for the growth and maintenance of bacterial cells were obtained  
5 from Aldrich Chemicals (Milwaukee, WI), DIFCO Laboratories (Detroit, MI), GIBCO/BRL (Gaithersburg, MD), or Sigma Chemical Company (St. Louis, MO) unless otherwise specified.

PCR reactions were run on GeneAMP PCR System 9700 using Amplitaq or Amplitaq Gold enzymes (PE Applied Biosystems, Foster City, CA). The  
10 cycling conditions and reactions were standardized according to manufacture's instructions.

The meaning of abbreviations is as follows: "sec" means second(s), "min" means minute(s), "h" means hour(s), "d" means day(s), "μL" means microliter,  
15 "mL" means milliliters, "L" means liters, "mM" means millimolar, "M" means molar, "mmol" means millimole(s), "Cm<sup>r</sup>" means chloramphenicol resistance, "cat" means chloroamphenicol acetyl transferase, "Amp<sup>r</sup>" means ampicillin resistance, "Amp<sup>s</sup>" means ampicillin sensitivity, "kb" means kilo base.

#### EXAMPLE 1

#### 20 Targeted Gene Replacement by Linear DNA Fragments for Site-directed Mutagenesis of *Escherichia coli*

Example 1 describes the cloning, mutation and integration of a mutant *yciK* gene into the *Escherichia coli* genome by homologous recombination using linearized mutant DNA.

#### 25 Isolation of *yciK* gene:

A 1460 bp fragment of DNA (SEQ ID NO:1, Figure 1) containing *yciK* gene was amplified using pCR-Script Amp Cloning kit from Stratagene (catalog #211188) from genomic DNA of *Escherichia coli* strain W3110 (Sigma; catalog #D0421). PCR amplification (Mullis and Faloona, *Methods Enzymol.*  
30 155:335-350 (1987)) was performed using oligonucleotides SEQ ID NO:2 and SEQ ID NO:3 as forward- and reverse primers, respectively (Figure 1). The PCR product was blunt-ended and ligated into *SrfI* site of cloning vector pCR-Script Amp SK(+) followed by transformation into XL-1 Blue MRF' Kan supercompetent cells. Transformed cells were plated on Luria-Bertani medium  
35 containing ampicillin, X-gal and IPTG. Plasmids were isolated from white, ampicillin-resistant transformants and tested for the presence of the insert by restriction digestion. One such plasmid, *yciKCK*, was subsequently confirmed

for the insert containing *yciK* gene by sequencing on ABI PRISM (Model 377, Version 2.1.1).

Cloning of *yciK* gene in a vector with suitable restriction sites:

5 The *yciK* DNA was used as a template with primers SEQ ID NO:4 and SEQ ID NO:5 to generate a DNA fragment (SEQ ID NO:6) containing *yciK* gene flanked with *Hind*III and *Xho*I restriction sites (Figure 1) for cloning in *Hind*III/*Xho*I restricted pBluescript II SK(+) vector (Stratagene; catalog #212205). The resultant plasmid was named pSCyciK1 (Figure 2).

*In vitro* disruption of *yciK* gene with insertional mutagenesis:

10 To disrupt *yciK* open reading frame (ORF), a *Hinc*II fragment (Figure 2) of the plasmid pSCyciK1 which encodes amino acids 124 to 189 of *yciK* ORF (total length=252 amino acids; SEQ ID NO:8) was replaced with a 1.2 kb *Hinc*II-*Sma*I fragment (bases 1-1225 of the SEQ ID NO:7 (see also Figure 3), constituting the sense strand of the selectable chloramphenicol-resistance encoding gene flanked  
15 by bacteriophage P1 *loxP* sites (Snaith et al., *Gene* 166:173-174 (1995) in plasmid pLoxCat1). This construction yielded two plasmids *yciKcat*2 (Figure 4) and *yciKcat*3 (Figure 5) containing *Cm<sup>r</sup>* ORF (*cat*) in opposite or same orientation as *yciK*, respectively.

20 Introduction of *yciK* mutation into *Escherichia coli* genome by homologous recombination using linearized mutant DNA:

The plasmid construct (*yciKcat*2 or *yciKcat*3) was digested with *Afl*III and *Xmn*I, followed by gel purification of a 3.9 kb band of linearized DNA fragments (Figures 3 and 4) containing mutant *yciK* gene. *Escherichia coli* strains FM5 (ATCC 53911) and KLP23 (FM5 *glpK-gldA*<sup>-</sup>) were electrotransformed with  
25 0.5 µg of the above 3.9 kb linear DNA and the resulting transformants were screened for double recombinant phenotype of chloramphenicol resistance (25 µg/mL) and ampicillin sensitivity (100 µg/mL) on LB medium. High numbers of transformants (roughly 10<sup>7</sup>-10<sup>9</sup>) were screened. Genomic DNA from *Cm<sup>r</sup>Amp<sup>s</sup>* colonies was dot blotted on Hybond N<sup>+</sup> positively charged nylon  
30 membrane (Amersham; catalog # RPN2020B). A 982 bp *Xba*I fragment (bases 58-1039 of SEQ ID NO:7 denote the sense strand) that contains *Cm<sup>r</sup>* encoding fragment, was used a probe. All *Cm<sup>r</sup>Amp<sup>s</sup>* colonies tested positive for the presence of DNA encoding chloramphenicol resistance gene under high stringency conditions (0.1 x SSC, 0.1% SDS, 60°C for 15 min). Probe labeling,  
35 hybridization and detection for dot blots and subsequent Southern blotting experiments, were performed using ECL random prime labelling and detection systems version II, (Amersham International plc, Buckinghamshire, England). Genomic DNA from randomly selected *Cm<sup>r</sup>Amp<sup>s</sup>* colonies, that also tested

positive for the presence of the *cat* (encodes chloramphenicol acetyl transferase) gene, was used as template for PCR reactions using oligonucleotide pair (SEQ ID NO:9 and SEQ ID NO:10; Figure 1). These primers were designed such that only genome-specific *yciK* (wild-type or mutant) amplification could occur. Plasmid-borne *yciK* (wild-type in pSCyciK1 or mutant in pyciKcat2/pyciKcat3) did not contain complementary sequences to these primers and as a result could not yield any PCR product. This design was for avoiding false positives. The DNA from mutant colonies yielded a 3.1 kb PCR product compared to 2.1 kb product from wild-type (SEQ ID NO: 17; Figure 6) confirming that *yciK* gene in the *Escherichia coli* genome contained an insertion as predicted by the construct design. The mutants were further authenticated by Southern hybridization of *Sst*II digested genomic DNA fragments (Figure 1) probed with 969 bp *Sst*II fragment of pyciKCK containing *yciK* DNA (SEQ ID NO:18). All the mutants yielded a 2.3 kb band compared to the 1.3 kb band (SEQ ID NO:19) of wild-type strains (Figure 7).

This Example demonstrated that several independent *yciK* knockouts were obtained using two different gene constructs and two different genetic backgrounds of *E. coli* hosts. FM204 was a FM5 derivative obtained by integrating linearized DNA from pyciKcat2; the FM5 integrants that resulted from the pyciKcat3 *Afl*III-*Xmn*I fragment were named FM301 and FM302. Similarly, KLP201 and KLP202 were KLP23 derivatives using pyciKcat2 fragments. KLP301 and KLP304 were also derived from KLP23 by using the fragment from pyciKcat3.

## EXAMPLE 2

### 25 Targeted Replacement of Mutant Gene with a Functional Gene Using Linear DNA Fragments

Linear DNA molecules can also be used to replace mutant genes with the wild-type gene. If a mutant has a phenotype of lack of growth under certain nutrient or environmental conditions, a replacement of wild-type gene can be selected by acquired ability for growth under same conditions. For example, *hemB* mutants of *Escherichia coli* and *Bradyrhizobium japonicum* require exogenously added hemin for growth (Chauhan, S. and O'Brian, M. R. (*J. Bacteriol.* 175:7222-7227 (1993)). A linear DNA fragment containing functional *hemB* gene from a homologous or heterologous source is amplified (by PCR or by cloning). The *Escherichia coli hemB* mutant strain RP523 (Li, J. M. et al., *J. Bacteriol.*, 170:1021-1025 (1988) is electrotransformed with the amplified linear(ized) DNA fragments that harbor functional *hemB* gene. Transformants are screened on LB plates for growth. Any colonies that appear are due to a

functional *hemB* gene in the genome. If insertional mutations are being replaced, genomic constructs are further tested by PCR amplification or Southern hybridizations of the region of DNA modified. If the insertion also contains a selectable marker, the transformants may be screened for the absence of the phenotype conferred by the selectable marker. In case a point mutation is to be replaced, the PCR amplified fragment is sequenced either directly or after cloning in a suitable vector (e.g. pBluescript II SK(+), Stratagene, Cat #212205) for the presence of wild-type sequence. This method is extremely beneficial for restoring specific gene functionality in a host strain that has gone through several sequential mutations in the genome.

### EXAMPLE 3

#### One-step PCR Method to Generate Linear DNA

##### Fragments for Site-directed Mutagenesis

Oligonucleotide pairs approximately 150 bases in length are synthesized. Up to 30 bp on the 3'-end of forward primer is identical to a region flanking the 5'-end of a selectable marker and the rest of the bases are identical to the 5' region of the gene to be disrupted. Up to 30 bp on the 3'-end of reverse primer are complementary to a region flanking the 3'-end of a selectable marker and the rest of the bases are identical to the 3' region of the gene to be disrupted. The above oligonucleotides are used in a PCR reaction to amplify DNA fragments that contain a marker gene flanked on each side with at least 20 bases of sequence homologous to the gene desired to be mutated. The PCR product is used to electrotransform wild-type *Escherichia coli* cells for generating mutants by homologous recombination which can be tested by methods described in Example 1.

### EXAMPLE 4

#### Engineering of Triosephosphate Isomerase Mutant of *Escherichia coli* KLP23

This example describes the construction of plasmid for triosephosphate isomerase gene replacement in *Escherichia coli* KLP23 and engineering of triosephosphate isomerase mutant RJ8m by linear DNA transformation.

##### Construction of plasmid for triosephosphate isomerase gene replacement in *Escherichia coli* KLP23:

*Escherichia coli* KLP23 genomic DNA was prepared using the Puregene DNA Isolation Kit (Gentra Systems, Minneapolis, MN). A 1.0 kb DNA fragment containing *cdh* and the 3' end of triosephosphate isomerase (*tpiA*) genes was amplified by PCR (Mullis and Faloona, *Methods Enzymol.* 155:335-350 (1987)) from KLP23 genomic DNA using primers (SEQ ID NO:11 and SEQ ID NO:12). A 1.0 kb DNA fragment containing the 5' end of *tpiA*, *yiiQ*, and the 5' end of *yiiR*

genes was amplified by PCR from KLP23 genomic DNA using primers SEQ ID NO:13 and SEQ ID NO:14. The first 26 bases at 5' end of primer SEQ ID NO:13 are complementary to the primer SEQ ID NO:12 to enable subsequent overlap extension PCR, followed by a *ScaI* (AGTACT) site. The next 28 bases following  
5 *ScaI* site at the 3' end of SEQ ID:13 reside on 5' end of the *tpiA* gene (Figure 8). The gene splicing by overlap extension technique (Horton et al., *BioTechniques* 8:528-535 (1990)) was used to generate a 2.0 kb fragment by PCR using the above two PCR fragments as templates and primers SEQ ID NO:11 and SEQ ID NO:14. This fragment represented a deletion of 73% of the 768 bp *tpiA* ORF.  
10 Overall, this fragment had 1.0 kb flanking regions on either side of the *ScaI* cloning site (within the partial *tpiA*) to allow for chromosomal gene replacement by homologous recombination.

The above blunt-ended 2.0 kb PCR fragment was cloned into the pCR-Blunt vector using the Zero Blunt PCR Cloning Kit (Invitrogen, San Diego,  
15 CA) to yield the 5.5 kb plasmid pRN106-2 (Figure 9) containing kanamycin and Zeocin resistance genes. The 1.2 kb *HincII* fragment (SEQ ID NO:7, Figure 3) containing a chloramphenicol-resistance gene flanked by bacteriophage P1 *loxP* sites (Snaith et al., *Gene* 166:173-174 (1995)), was used to interrupt the *tpiA* fragment in plasmid pRN106-2 by ligating it to *ScaI*-digested plasmid pRN106-2  
20 to yield the 6.8 kb plasmid pRN107-1 (Figure 10).

Engineering of triosephosphate isomerase mutant (RJ8m) by linear DNA transformation:

Using pRN107-1 as template and primers SEQ ID NO:11 and SEQ ID NO:14, the 3.2 kb fragment containing *tpiA* flanking regions and chloramphenicol  
25 resistance marker (SEQ ID NO:7) was PCR-amplified and gel-extracted. *Escherichia coli* KLP23 was electrotransformed with about 1 µg of this 3.2 kb linear DNA fragment. Transformants that were chloramphenicol-resistant (12.5 µg/mL) and kanamycin-sensitive (30 µg/mL) were further screened on M9 minimal media for poor glucose utilization on 1 mM glucose, a phenotype  
30 expected for *tpiA* mutant. An *EcoRI* digest of genomic DNA from one such mutant, RJ8m, was probed with the intact *tpiA* gene via Southern analysis (Southern, *J. Mol. Biol.* 98:503-517 (1975)). The results indicated that it was a double-crossover integrant (*tpiA* gene replacement) as the two expected 6.6 kb and 3.0 kb bands were observed, owing to the presence of an additional *EcoRI* site  
35 within the chloramphenicol resistance gene. As expected, the host KLP23 and wild-type FM5 controls yielded single 8.9 kb and 9.4 kb bands respectively. This *tpiA* mutant was further analyzed by genomic PCR using primers SEQ ID NO:15 and SEQ ID NO:16 (Figure 11), which yielded the expected 4.6 kb PCR fragment

while for the same primer pair the host KLP23 and wild-type FM5 strains both yielded the expected 3.9 kb PCR fragment. When cell-free extracts from *tpiA* mutant RJ8m and host KLP23 were tested for *tpiA* activity using glyceraldehyde 3-phosphate as substrate, no activity was observed with RJ8m. Taken together, a  
5 confirmation of *tpiA* knockout was demonstrated.

CLAIMS

1. A method for gene replacement in recombination-proficient bacteria comprising:
  - (a) transforming recombination-proficient bacteria with a replacement cassette containing 5' and 3' flanking sequences, each flanking sequence independently with at least 75% identity to the target DNA; and
  - (b) screening for an altered phenotype.
2. The method of Claim 1 in which absolute recombination frequencies are at least  $10^{-4}$  to enable selection of double homologous recombination event(s).
3. The method of Claim 1 in which the transforming step is performed chemically or by electroporation.
4. The method of Claim 1 in which the recombination-proficient bacteria are enteric bacteria.
5. A method of gene disruptions in recombination-proficient enteric bacteria comprising transforming the recombination-proficient enteric bacteria with a replacement cassette containing 5' and 3' flanking sequences, each flanking sequence independently with at least 75% identity to the target DNA.
6. A method of replacing mutant genes with functional genes in recombination-proficient enteric bacteria comprising transforming recombination-proficient bacteria with a replacement cassette containing 5' and 3' flanking sequences, each flanking sequence independently with at least 75% identity to the target DNA.
7. A method of regulating complex operons comprising deleting or replacing one or more promoter regions operably linked to the complex operon with at least one alternate desired promoter region.
8. A method according to any one of Claims 1, 2, 3, 4, or 5 for gene replacement in recombination-proficient bacteria further comprising: prior to transforming the recombination-proficient the replacement cassette is generated using direct PCR of a selection marker wherein the direct PCR uses long primer pairs, each primer having at least 75% identity to the target DNA at the 5' end and at least 75% identity to the selection marker at the 3' end.




FIG. 1



2/11




FIG. 2




FIG. 3

H = HincIII  
Xb = XbaI  
Sm = SmaI

FIG. 4





FIG. 5



Confirmation of mutants by PCR




FIG. 6





FIG. 7

**Step 1:**


Generation of 1 kb template fragments having 3' complementary ends using primer pairs SEQ ID NO: 11 - SEQ ID NO: 12 and SEQ ID NO: 13 - SEQ ID NO: 14. The 5' end of SEQ ID NO: 13 is complementary to SEQ ID NO: 12. A Scal restriction site was engineered into SEQ ID NO: 13.



**FIG. 8-1**

**Step 2:**

Overlap-Extension PCR generation of 2 kb DNA fragment using above 1 kb template fragments resulted from annealing of 3' complementary ends followed by 5' to 3' extension of both DNA strands to yield the final 2 kb DNA product. Further rounds of PCR with this 2 kb template and primers SEQ ID NO: 11 and SEQ ID NO: 14 resulted in amplification of this 2 kb DNA fragment that represented a deletion of 73% of the tpiA structural gene with a unique ScaI cloning site within.



**FIG. 8-2**




FIG. 8-3

9/11

FIG. 9





FIG. 10





KLP23




FIG. 11-1

RJ8m (KLP23 tpiA--)




FIG. 11-2

SEQUENCE LISTING

- <110> E. I. du Pont de Nemours and Company
- <120> Targeted Gene Replacements in Enteric Bacteria Using Linear DNA
- <130> BC1010 PCT
- <140>
- <141>
- <150> 60/141,103
- <151> 1999-06-25
- <160> 19
- <170> Microsoft Office 97
- <210> 1
- <211> 1460
- <212> DNA
- <213> Escherichia coli
  
- <400> 1

cataaagccc	caaagtcata	aagtacactg	gcagcgcgac	agacaacgtc	gttgaggagt	60
agccatgcat	taccagccaa	aacaagattt	actcaatgat	cgcattatcc	tggtgacggg	120
agccagcgat	ggtattggtc	gtgaagccgc	gatgacgtat	gcacgctatg	gtgcgacagt	180
gattctggtg	ggccgtaatg	aagaaaaatt	acgtcaggta	gccagccaca	taaacgaaga	240
aactgggctg	cagccacagt	ggtttattct	cgatttgctg	acctgcacgt	ccgaaaattg	300
ccaacaactg	gcacagcgca	ttgccgttaa	ttatccgcgt	ctggatggtg	ttttgcataa	360
tgccggattg	ctcggcgatg	tttgcccaat	gagcgaacaa	aatccgcagg	tctggcagga	420
cgtcatgcag	gtcaacgtta	atgccacctt	tatgctcacc	caggcactgc	ttcctttatt	480
actcaaatcg	gacgccggtt	cactggtcct	tacttcatca	agcgttggac	gtcagggacg	540
agccaactgg	ggtgcatatg	cagcgtcgaa	atgtgccacc	gaagggatga	tgcaggtact	600
ggccgatgaa	tatcagcagc	gcctgcgtgt	caactgcatt	aaccagcg	gtacgcgcac	660
cgcaatgcgt	gccagcgcct	tcccagccga	agatccacag	aaacttaaaa	caccgcctga	720
tatcatgccg	ctctacctct	ggctgatggg	cgatgacagc	cgccgtaaaa	ccggcatgac	780
ctttgacgcc	caaccgggcc	gtaaacccagg	aatttcccaa	tgagtgatga	acgctaccaa	840
cagcgtcagc	agcgagttaa	agaaaaagta	gatgctcgtg	tggcccaggc	ccaggatgaa	900
cgcggtatta	tcacgtcttt	taccggcaat	ggaaaaggca	aaaccaccgc	ggcatttggg	960
acggcaacac	gcgcagttgg	tcacggaaaa	aaagtaggcg	tcgtgcagtt	tattaaaggc	1020
acctggccta	atggcgaacg	caatctgctg	gagccacatg	gcgttgagtt	tcaggatgat	1080
gcaacgggct	ttacctggga	tacacaaaac	cgcgagtctg	ataccgccgc	ctgccgcgaa	1140
gtctggcaac	atgcaaagcg	gatgcttctt	gattcctcac	tggatatggt	tttgcttgat	1200
gaactgacgt	atatggtggc	gtatgactat	ttgccactgg	aagaagtgg	gcagggcgtta	1260
aatgaacgtc	cacatcaaca	gacggtgatt	atcacgggtc	gtggttgtca	tcgggatatt	1320
cttgaactgg	cagatacggg	aagtgaatta	cgccccgtca	aacatgcggt	tgatgccggg	1380
gtaaaagcgc	agatagggat	cgattattaa	tctgtaaaaa	tgccggatat	gacgtccggc	1440
atactttgat	taaccgttat					1460

  
- <210> 2
- <211> 30
- <212> DNA
- <213> Primer
  
- <400> 2

cataaagccc	caaagtcata	aagtacactg				30
------------	------------	------------	--	--	--	----

  
- <210> 3
- <211> 29
- <212> DNA
- <213> Primer

<400> 3  
 ataacggtta atcaaagtat gccggagtc 29

<210> 4  
 <211> 33  
 <212> DNA  
 <213> primer

<400> 4  
 aggaagcttg ccccaaagtc ataaagtaca ctg 33

<210> 5  
 <211> 33  
 <212> DNA  
 <213> primer

<400> 5  
 atactcgagg ttaatcaaag tatgccggac gtc 33

<210> 6  
 <211> 1466  
 <212> DNA  
 <213> Escherichia coli

<400> 6  
 aggaagcttg ccccaaagtc ataaagtaca ctggcagcgc gacagacaac gtcggtgagg 60  
 agtagccatg cattaccagc caaaacaaga tttactcaat gatcgcatta tcttgggtgac 120  
 gggagccagc gatggtattg gtcgtgaagc cgcgatgacg tatgcacgct atgggtgcgac 180  
 agtgattctg ttgggccgta atgaagaaaa attacgtcag gtagccagcc acataaacga 240  
 agaaactggg cgtcagccac agtggtttat tctcgatttg ctgacctgca cgtccgaaaa 300  
 ttgccaaaca ctggcacagc gcattgccgt taattatccg cgtctggatg gtgttttgca 360  
 taatgccgga ttgctcggcg atgtttgcc aatgagcga caaaatccgc aggtctggca 420  
 ggacgtcatg caggtcaacg ttaatgccac ctttatgctc acccaggcac tgcttccttt 480  
 attactcaaa tcggagcgcg gttcactggt ctttacttca tcaagcgttg gacgtcaggg 540  
 acgagccaac tggggtgcat atgcagcgtc gaaatttgcc accgaaggga tgatgcaggt 600  
 actggccgat gaatatcagc agcgcctgcg tgtcaactgc attaaccag gcggtacgcg 660  
 caccgcaatg cgtgccagcg ccttcccgc cgaagatcca cagaaactta aaacaccgcg 720  
 tgatatcatg ccgctctacc tctggctgat gggcgatgac agccgccgta aaaccggcat 780  
 gacctttgac gcccaaccgg gccgtaaacc aggaatttcc caatgagtga tgaacgctac 840  
 caacagcgtc agcagcaggt gaaagaaaa gtatgctc gtgtggccca ggcccaggat 900  
 gaacgcggta ttatcatcgt ctttaccggc aatggaaaag gcaaaaaccac cgcggcattt 960  
 ggtacggcaa cacgcgcagt tggtcacgga aaaaaagtag gcgtcgtgca gtttattaaa 1020  
 ggacactggc ctaattggcg acgcaatctg ctggagccac atggcgttga gtttcaggtg 1080  
 atggcaacgg cgtttacctg ggatacacia aaccgcgagt ctgataccgc cgcctgccc 1140  
 gaagtctggc aacatgcaaa gcggatgctt gctgattcct cactggatat ggttttgctt 1200  
 gatgaactga cgtatatggt ggcgtatgac tatttgccac tggagaagt ggtgcaggcg 1260  
 ttaaatgaac gtccacatca acagacgggtg attatcacgg gtcgtggttg tcatcgggat 1320  
 attcttgaac tggcagatac ggtaagtga ttacgccccg tcaaacatgc gtttgatgcc 1380  
 ggtgtaaaaag cgcagatagg gatcgattat taatctgtaa aaatgccgga tatgacgtcc 1440  
 ggcatacttt gattaacctc gagtat 1466

<210> 7  
 <211> 1247  
 <212> DNA  
 <213> Plasmid

<400> 7  
 gacggtatcg ataagctgga tccataaact cgtataatgt atgctatacg aagttatcta 60  
 gagtccgaat aaatacctgt gacggaagat cacttcgcag aataaataaa tcttgggtgct 120  
 cctggtgata ccgggaagcc ctgggccaac ttttggcgaa aatgagacgt tgatcggcac 180  
 gtaagagggt ccaactttca ccataatgaa ataagatcac taccgggctg attttttgag 240  
 ttatcgagat tttcaggagc taaggaagct aaaatggaga aaaaaatcac tggatatacc 300  
 accggtgata tatcccaatg gcatcgtaaa gaacattttg aggcatttca gtcagttgct 360  
 caatgtacct ataaccagac cgttcagctg gatattacgg cctttttaa gaccgtaaag 420

```

aaaaataagc acaagtttta tccggccttt attcacattc ttgcccgcct gatgaatgct 480
catccggaat tccgtatggc aatgaaagac ggtgagctgg tgatatggga tagtggtcac 540
ccttggttaca ccgttttcca tgagcaaact gaaacgtttt catcgctctg gagtgaatac 600
cacgacgatt tccggcagtt tctacacata tattcgcaag atgtggcggtg ttacggtgaa 660
aacctggcct atttccctaa agggtttatt gagaatatgt ttttcgtctc agccaatccc 720
tgggtgagtt tcaccagttt tgatttaaac gtggccaata tggacaactt cttcgcccc 780
gttttcaccc atgggcaaatt attatacgca aggcgacaag gtgctgatgc cgctggcgat 840
tcaggttcat catgccgtct gtgatggctt ccatgtcggc agaatgctta atgaattaca 900
acagtactgc gatgagtggc agggcggggc gtaatttttt taaggcagtt attggtgccc 960
ttaaacgcct ggtgctacgc ctgaataagt gataataagc ggatgaatgg cagaaattcg 1020
gacctgcagg catgcaactc tagataactt cgtataatgt atgctatacg aagttatgcy 1080
gocgccatat gcctcctagg cctattaata ttccggagta tacgtagccg gctaacgttc 1140
tagcatgcga aatttaaagc gctgatatcg atcgcgcgca gatctgtcat gatgatcatt 1200
gcaattggat ccatatatag ggcccggggt tataattacc tcaggtc 1247

```

```

<210> 8
<211> 252
<212> PRT
<213> Escherichia coli

```

```

<400> 8
Met His Tyr Gln Pro Lys Gln Asp Leu Leu Asn Asp Arg Ile Ile Leu
 1          5          10          15

Val Thr Gly Ala Ser Asp Gly Ile Gly Arg Glu Ala Ala Met Thr Tyr
          20          25          30

Ala Arg Tyr Gly Ala Thr Val Ile Leu Leu Gly Arg Asn Glu Glu Lys
          35          40          45

Leu Arg Gln Val Ala Ser His Ile Asn Glu Glu Thr Gly Arg Gln Pro
          50          55          60

Gln Trp Phe Ile Leu Asp Leu Leu Thr Cys Thr Ser Glu Asn Cys Gln
          65          70          75          80

Gln Leu Ala Gln Arg Ile Ala Val Asn Tyr Pro Arg Leu Asp Gly Val
          85          90          95

Leu His Asn Ala Gly Leu Leu Gly Asp Val Cys Pro Met Ser Glu Gln
          100          105          110

Asn Pro Gln Val Trp Gln Asp Val Met Gln Val Asn Val Asn Ala Thr
          115          120          125

Phe Met Leu Thr Gln Ala Leu Leu Pro Leu Leu Leu Lys Ser Asp Ala
          130          135          140

Gly Ser Leu Val Phe Thr Ser Ser Ser Val Gly Arg Gln Gly Arg Ala
          145          150          155          160

Asn Trp Gly Ala Tyr Ala Ala Ser Lys Phe Ala Thr Glu Gly Met Met
          165          170          175

Gln Val Leu Ala Asp Glu Tyr Gln Gln Arg Leu Arg Val Asn Cys Ile
          180          185          190

Asn Pro Gly Gly Thr Arg Thr Ala Met Arg Ala Ser Ala Phe Pro Thr
          195          200          205

Glu Asp Pro Gln Lys Leu Lys Thr Pro Ala Asp Ile Met Pro Leu Tyr
          210          215          220

```

Leu Trp Leu Met Gly Asp Asp Ser Arg Arg Lys Thr Gly Met Thr Phe  
 225 230 235 240

Asp Ala Gln Pro Gly Arg Lys Pro Gly Ile Ser Gln  
 245 250

<210> 9  
 <211> 22  
 <212> DNA  
 <213> primer

<400> 9  
 cagacaacaa ttccacgagt cc 22

<210> 10  
 <211> 22  
 <212> DNA  
 <213> primer

<400> 10  
 tgaagttgaa cgtgaatatg cc 22

<210> 11  
 <211> 28  
 <212> DNA  
 <213> primer

<400> 11  
 tcaaaccggg tggtttctcg cgaccggg 28

<210> 12  
 <211> 28  
 <212> DNA  
 <213> primer

<400> 12  
 ctcagccgga tatcgacggc gcgctggt 28

<210> 13  
 <211> 60  
 <212> DNA  
 <213> primer

<400> 13  
 accagcgcgc cgtcgatatc cggctgagta ctcaacacct gccagctctt tacgcaggtt 60

<210> 14  
 <211> 28  
 <212> DNA  
 <213> Primer

<400> 14  
 cagcatgcct gcgaaccaca ggcctatc 28

<210> 15  
 <211> 28  
 <212> DNA  
 <213> Primer

<400> 15  
 atgaacaagt ggggcgtagg gttaacat 28

<210> 16  
 <211> 28

<212> DNA  
 <213> Primer

<400> 16  
 ttaattactt gatttattgt cggettta

28

<210> 17  
 <211> 2095  
 <212> DNA  
 <213> Escherichia coli

<400> 17  
 cagacaacaa ttccacgagt cccacacctg gttaaacaac gctttggctc acagtttaca 60  
 acaggcatgt taagccgtct cgagagatg ttattgcagc gaaagtatga caaagtatcc 120  
 attttgcggt gttatcgccc caggctgatt gaaatgccct tctgtttcag gcataaagcc 180  
 ccaaagtcac aaagtacact ggcagcgcga cagacaacgt cgttgaggag tagccatgca 240  
 ttaccagcca aaacaagatt tactcaatga tcgcattatc ctggtgacgg gagccagcga 300  
 tggattgggt cgtgaagccg cgatgacgta tgcacgctat ggtgcgacag tgattctggt 360  
 gggccgtaat gaagaaaaat tacgtcaggt agccagccac ataaacgaag aaactgggcg 420  
 tcagccacag tggttttattc tcgatttgct gacctgcacg tccgaaaatt gccacaact 480  
 ggcacagcgc attgccgcta attatccgcg tctggatggt gttttgcata atgccggatt 540  
 gctcggcgat gtttgcccaa tgagcgaaca aaatccgcag gtctggcagg acgtcatgca 600  
 ggtcaacggt aatgccacct ttatgctcac ccaggcactg cttcctttat tactcaaact 660  
 ggacgcoggt tcaactggtct ttacttcatc aagcgttggc cgtcagggac gagccaactg 720  
 gggtgcatat gcagcgtcga aatttgccac cgaagggatg atgcaggta tggccgatga 780  
 atatcagcag gcctgcgtg tcaactgcat taaccaggc ggtacgcgca ccgcaatgcg 840  
 tgcacgcgcc ttcccgaccg aagatccaca gaaacttaaa acaccgcgtg atatcatgcc 900  
 gctctacctc tggctgatgg gcgatgacag ccgccgtaaa accggcatga cttttgacgc 960  
 ccaaccgggc cgtaaaccag gaatttccca atgagtgatg aacgctacca acagcgtcag 1020  
 cagcgagtga aagaaaaagt agatgctcgt gtggcccagg cccaggatga acgcggtatt 1080  
 atcatcgtct ttaccggcaa tggaaaaggc aaaaccaccg cggcatttgg tacggcaaca 1140  
 cgcgcagttg gtcacggaaa aaaagtaggc gtcgtgcagt ttattaaagg cacctggcct 1200  
 aatggcgtaac gcaatctgct ggagccacat ggcggtgagt ttcaggatg ggcaacgggc 1260  
 tttacctggg atacacaaaa ccgcgagtct gataccgccg cctgccgca agtctggcaa 1320  
 catgcaaagc ggatgcttgc tgattcctca ctggatatgg ttttgcttga tgaactgacg 1380  
 tatatggtgg cgtatgacta tttgccaactg gaagaagtgg tgcagggcgtt aaatgaacgt 1440  
 ccacatcaac agacggatg tatcacgggt cgtggttgtc atcgggatat tcttgaactg 1500  
 gcagatacgg taagtgaatt acgccccgtc aaacatgcgt ttgatgccgg tgtaaaagcg 1560  
 cagataggga tcgattatta atctgtaaaa atgccggata tgacgtccgg catactttga 1620  
 ttaaccgta ttattacgtc cgccagaacg acgaccgccg ctcaactgac tgtgacgttt 1680  
 caccgcacga cgaatctgat tcgccttcat gcgacgcagg tctttttcta cagcgacttt 1740  
 agagctggtt tctggcggtg gctccaccag ttgcgcgaga tagttagtct gggcgaggct 1800  
 cagctccgtc cagccaccgc gtggcagacc ttttggcagt gggatatcac cgtaacgaac 1860  
 acggatcagg cggctcacct gcacaccaac cgcttcccac agacgacgaa cttcacgggt 1920  
 acggccttgc gtcagagtca cgttgtaacca ctggttgatc ccttcgcccgc cgtggaactt 1980  
 gatggtttta aaagctgccg gaccatcttc caactgcacg aatcacgcag 2040  
 ttcgcgctcg tcaacctgac caaatacacg cacggcatat tcacgttcaa cttca 2095

<210> 18  
 <211> 969  
 <212> DNA  
 <213> Escherichia coli

<400> 18  
 ggtggcggcc gctctagccc ataaagcccc aaagtcataa agtacactgg cagcgcgaca 60  
 gacaacgtcg ttgaggagta gccatgcatt accagccaaa acaagattta ctcaatgatc 120  
 gcattatcct ggtgacggga gccagcgatg gtattggtcg tgaagccgcg atgacgatg 180  
 cacgctatgg tgcgacagtg attctgttgg gccgtaatga agaaaaatta cgtcaggtag 240  
 ccagccacat aaacgaagaa actgggctc agccacagtg gtttattctc gatttgctga 300  
 cctgacgtc cgaatttgc caacaactgg cacagcgcac tgcggtaat tgcccaatg tatccgctc 360  
 tggattgggt tttgcataat gccggattgc cagcgatgt ttgcccattg agcgaacaaa 420  
 atccgcaggt ctggcaggac gtcatgcagg tcaacgttaa tgccacctt atgotcacc 480  
 aggcaactgt tcctttatta ctcaaactcg acgccggttc actggtcttt acttcatcaa 540  
 gcggttgacg tcagggacga gccaaactgg gtgcatatgc agcgtcgaat tttgccaccg 600

```

aagggatgat gcaggtactg gccgatgaat atcagcagcg cctgcgtgtc aactgcatta 660
accagggcgg tacgcgcacc gcaatgcgtg ccagcgcctt cccgaccgaa gatccacaga 720
aacttaaaac acccgctgat atcatgccgc tctacctctg gctgatgggc gatgacagcc 780
gccgtaaaac cggcatgacc tttgacgccc aaccggggccg taaaccagga atttcccaat 840
gagtgatgaa cgctaccaac agcgtcagca gcgagtgaaa gaaaaagtag atgctcgtgt 900
ggcccaggcc caggatgaac gcggtattat catcgtcttt accggcaatg gaaaaggcaa 960
aaccaccgc
    
```

```

<210> 19
<211> 1282
<212> DNA
<213> Escherichia coli
    
```

```

<400> 19
ggccagtctt tctttcatct cttatactg ttcgctgaga ttggtgacct gtaactogcc 60
acgctggcgt ttattacggt gagcaacatt gacaataatg gcggcaatcg ccgcaatcgc 120
tagcacaacg gtaacgattt tcgcaaaaaa caaaccataat tcagacaaca attccacgag 180
tccccacctt ggtaaacaac cgctttggct cacagtttac aacaggcatg ttaagccgctc 240
tcgcagagat gttattgcag cgaaagtatg acaaagtatc cattttgcgg tgttatcgcc 300
ccaggctgat tgaaatgccc ttctgtttca ggcataaagc cccaaagtca taaagtacac 360
tggcagcgcg acagacaacg tcggtgagga gtagccatgc attaccagcc aaaacaagat 420
ttactcaatg atcgcattat cctggtgacg ggagccagcg atggtattgg tcgtgaagcc 480
gcgatgacgt atgcacgcta tgggtgcgaca gtgattctgt tgggcccgtaa tgaagaaaaa 540
ttacgtcagg tagccagcca cataaacgaa gaaactgggc gtcagccaca gtggtttatt 600
ctcgatttgc tgacctgcac gtccgaaaat tgccaacaac tggcacagcg cattgccggt 660
aattatccgc gtctggatgg tgttttgcat aatgccggat tgctcggcga tgtttgccca 720
atgagcgaac aaaatccgca ggtctggcag gacgtcatgc aggtcaacgt taatgccacc 780
ttatgctca cccaggcact gcttccttta ttactcaaat cggacgcggg ttcactggtc 840
ttacttcat caagcgttgg acgtcagga cgagccaact ggggtgcata tgcagcgtcg 900
aaatthgcca ccgaagggat gatgcaggta ctggccgatg aatatcagca gcgcctgcgt 960
gtcaactgca ttaaccagg cggtacgcgc accgcaatgc gtgccagcgc cttcccagacc 1020
gaagatccac agaaacttaa aacaccgcgt gatatcatgc cgctctacct ctggctgatg 1080
ggcgatgaca gccgcccgtaa aaccggcatg acctttgacg cccaaccggg ccgtaaacca 1140
ggaatthccc aatgagtgat gaacgctacc aacagcgtca gcagcgagtg aaagaaaaag 1200
tagatgctcg tgtggcccag gccaggatg aacgcggtat tatcatcgtc ttaccggca 1260
atggaaaagg caaaaccacc gc
    
```



# INTERNATIONAL SEARCH REPORT

Internatic Application No
PCT/US 00/17154

**A. CLASSIFICATION OF SUBJECT MATTER**  
 IPC 7 C12N15/10 C12N15/90 C12N15/67

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
 IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 23238 A (AMGEN INC) 14 May 1999 (1999-05-14) see whole document, particularly page 5, lines 21-22, page 7, lines 18-19, page 8, lines 11-13, and page 20, line 13. ---	1-8
X	WO 98 42727 A (STANFORD RES INST INT) 1 October 1998 (1998-10-01) See whole document, particularly the abstract, page 19, lines 21-22, page 25, lines 13-16, page 44, lines 19-21, and page 50, lines 5-7. --- -/--	1-8

Further documents are listed in the continuation of box C.       Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family
---	---

Date of the actual completion of the international search  10 October 2000	Date of mailing of the international search report  24/10/2000
--	--

Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer  Smalt, R
--	------------------------------------

## INTERNATIONAL SEARCH REPORT

Internatio Application No

PCT/US 00/17154

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MURPHY, K.C.: "Use of bacteriophage lambda recombination funtions to promote gene replacement in Escherichia coli." JOURNAL OF BACTERIOLOGY, vol. 180, no. 8, April 1998 (1998-04), pages 2063-71, XP002149589	1-6,8
Y	the whole document	7
Y	WO 90 12098 A (CETUS CORP) 18 October 1990 (1990-10-18) page 5, line 28 - line 30; example XVI page 17, line 3 - line 5 page 69, line 5 - line 6 page 74, line 17 - line 29	7
X	SHIROZA T ET AL: "Application of the resident plasmid integration technique to construct a strain of Streptococcus godronii able to express the Bacillus circulans cycloisomaltooligosaccharide glucanotransferase gene, and secrete its active gene product" GENE: AN INTERNATIONAL JOURNAL ON GENES AND GENOMES,GB,ELSEVIER SCIENCE PUBLISHERS, BARKING, vol. 207, no. 2, 30 January 1998 (1998-01-30), pages 119-126, XP004108909 ISSN: 0378-1119 the whole document	1-6
X	US 5 530 191 A (MALIGA PAL) 25 June 1996 (1996-06-25) column 24, line 13 - line 16	7
X	WHITE A P ET AL: "High efficiency gene replacement in Salmonella enteritidis: chimeric fimbrins containing a T-cell epitope from Leishmania major" VACCINE,GB,BUTTERWORTH SCIENTIFIC. GUILDFORD, vol. 17, no. 17, 23 April 1999 (1999-04-23), pages 2150-2161, XP004165000 ISSN: 0264-410X the whole document	1-6,8
X	EL KAROUI MERIEM ET AL: "Gene replacement with linear DNA in electroporated wild-type Escherichia coli." NUCLEIC ACIDS RESEARCH, vol. 27, no. 5, 1 March 1999 (1999-03-01), pages 1296-1299, XP002149590 ISSN: 0305-1048 the whole document	1-6

# INTERNATIONAL SEARCH REPORT

Internatio Application No PCT/US 00/17154
--

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 837 528 A (PERO JANICE G ET AL) 17 November 1998 (1998-11-17) column 12, line 47 - line 51; example 8 -----	7
P, X	WO 99 66035 A (ICONIX PHARMACEUTICALS INC) 23 December 1999 (1999-12-23) the whole document -----	1-6, 8

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/17154

Patent document cited in search report		Publication date	Patent family member(s)	Publication date			
WO 9923238	A	14-05-1999	US 6090629	A 18-07-2000			
			AU 7606598	A 24-05-1999			
			EP 1030930	A 30-08-2000			
WO 9842727	A	01-10-1998	US 5948653	A 07-09-1999			
			AU 6562098	A 20-10-1998			
			EP 0977771	A 09-02-2000			
			US 6074853	A 13-06-2000			
WO 9012098	A	18-10-1990	AT 161049	T 15-12-1997			
			AU 5437390	A 05-11-1990			
			CA 2014264	A 12-10-1990			
			DE 69031803	D 22-01-1998			
			DE 69031803	T 09-07-1998			
			DK 471687	T 24-08-1998			
			EP 0471687	A 26-02-1992			
			ES 2111536	T 16-03-1998			
			JP 7073500	B 09-08-1995			
			NZ 233312	A 26-03-1992			
			US 5268274	A 07-12-1993			
			US 5530191	A	25-06-1996	AU 687544	B 26-02-1998
						AU 2198195	A 09-10-1995
BR 9507180	A 14-10-1997						
CA 2186164	A 28-09-1995						
CN 1148869	A 30-04-1997						
EP 0805852	A 12-11-1997						
JP 9510615	T 28-10-1997						
NZ 283622	A 19-12-1997						
PL 316435	A 06-01-1997						
RU 2139347	C 10-10-1999						
WO 9525787	A 28-09-1995						
US 5837528	A	17-11-1998				US 5925538	A 20-07-1999
						AT 195971	T 15-09-2000
			CN 1049185	A 13-02-1991			
			DE 69033616	D 05-10-2000			
			EP 0405370	A 02-01-1991			
			EP 1001026	A 17-05-2000			
			JP 3117489	A 20-05-1991			
			JP 10066562	A 10-03-1998			
WO 9966035	A	23-12-1999	AU 4694399	A 05-01-2000			